9 recruiting, 4 completed, 3 active not recruiting, 3 unknown. 21 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Recruiting 9, Completed 4, Active not recruiting 3, Unknown 3, Terminated 2 |
| Phase 2 | 7 | Recruiting 4, Completed 1, Terminated 1, Unknown 1 |
Follow Solid Carcinoma: new trials by email Literature Review of Solid Carcinoma trials Research Report on Solid Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers MSK-TCR5 - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-06-09 | 2026-11-02 |
| Imaging of Solid Tumors Using 18F-TRX 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Rahul Aggarwal | 56 | 2025-07-03 | 2026-07-23 |
| PET [89Zr]DFO-starPEG in Solid Tumors 89-zr-dfo-star polyethylene glycol (StarPEG), Whole Body Positron Emission Tomography (PET), Specimen Collection - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 13 | 2025-06-02 | 2026-06-05 |
| A Study of DM002 in Patients With Advanced Solid Tumors DM002 - Ovarian Neoplasms, Prostatic Neoplasms | Phase 1 / Phase 2 | Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 280 | 2025-02-17 | 2026-08-07 |
| A Study of DM005 in Patients With Advanced Solid Tumors DM005 - Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Recruiting | Doma Biopharmaceutical（Suzhou）Co., Ltd. | 208 | 2024-10-31 | 2026-08-07 |
| A Study of DM001 in Patients With Advanced Solid Tumors DM001 - Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 128 | 2024-10-24 | 2026-08-28 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-11-04 |
| A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer AZD1390, Stereotactic Body Radiotherapy - Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2023-05-17 | 2026-05-18 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors CF33-hNIS, Pembrolizumab, Modified FOLFOX - Solid Tumor, Solid Carcinoma | Phase 1 | Terminated | Imugene Limited | 66 | 2022-05-17 | 2026-03-06 |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Mirdametinib, Fulvestrant - Breast Cancer, Breast Cancer Stage IV | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 6 | 2021-09-14 | 2025-05-23 |
| An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors INV-1120, Pembrolizumab - Cancer, Solid Tumor, Adult | Phase 1 | Recruiting | Shenzhen Ionova Life Sciences Co., Ltd. | 78 | 2020-06-26 | 2026-03-18 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer GZ17-6.02, Capecitabine - Advanced Cancer, Gastric Cancer | Phase 1 | Unknown | Genzada Pharmaceuticals USA, Inc. | 127 | 2019-03-01 | 2022-12-23 |
| Oral AMXT 1501 Dicaprate in Combination With DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 | Completed | Aminex Therapeutics, Inc. | 56 | 2018-06-12 | 2023-05-25 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Minnelide™Capsules - Advanced Cancer, Gastric Cancer | Phase 1 | Unknown | Minneamrita Therapeutics LLC | 66 | 2017-10-10 | 2023-10-18 |
| PEN-866 in Patients With Advanced Solid Malignancies PEN-866 Sodium, fluorouracil, Folinic acid - Carcinoma, Endometrial Adenocarcinoma | Phase 1 / Phase 2 | Unknown | Tarveda Therapeutics | 340 | 2017-08-29 | 2022-02-17 |
Showing 20 of 21. Sign in to see all of them.
Neoplasm Metastasis (9) · Breast Neoplasms (6) · Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Stomach Neoplasms (4) · Colonic Neoplasms (3) · Pancreatic Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Endometrial Neoplasms (2) · Glioma (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2)
Neoplasms by Site (16) · Neoplasms (14) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (10) · Digestive System Diseases (9) · Neoplastic Processes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Carcinoma (8) · Digestive System Neoplasms (8) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (7) · Intestinal Diseases (7) · Intestinal Neoplasms (7) · Breast Diseases (6)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · ALX148 (1) · AZD1390 (1) · Biopsy (1) · Blood Specimen Collection (1) · Capecitabine (1) · Cetuximab (1) · Fluorouracil (1) · Fulvestrant (1) · Gemcitabine (1) · IFL protocol (1) · Leucovorin (1)
Memorial Sloan Kettering Cancer Center (4) · Aminex Therapeutics, Inc. (2) · Robert Flavell, MD, PhD (2) · Xadcera Biopharmaceutical (Suzhou) Co., Ltd. (2) · Doma Biopharmaceutical（Suzhou）Co., Ltd. (1) · Genzada Pharmaceuticals USA, Inc. (1) · Ikena Oncology (1) · Imugene Limited (1) · Institut de Recherches Internationales Servier (1) · Minneamrita Therapeutics LLC (1) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · QuantumLeap Healthcare Collaborative (1) · Rahul Aggarwal (1) · Shenzhen Ionova Life Sciences Co., Ltd. (1) · Tarveda Therapeutics (1)
United States (20) · Australia (6) · China (1) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Adam Schoenfeld, MD (1) · Anish Thomas, MD (1) · Daniel Higginson, MD (1) · Ezra Rosen, MD, PhD (1) · Jackie Walling, MBChB PhD (1) · Jordan Jacobs, MBA (1) · Karim Malek, MD (1) · Kathryn Gazarik (1) · Michael Armstrong, MD (1) · Nicole Gallegos, BS, MBA (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Rahul Aggarwal, MD (1) · Robert Flavell, MD (1) · Robert Flavell, MD, PhD (1)
PMID 33888901, PMID 35276694, PMID 38008031, PMID 38758815, PMID 40913836
2025 (1), R01CA266666 (1)